Dividend stocks: LIC, Hero MotoCorp to Lupin — these shares to trade ex-date soon

 22 Jul 2025 04:06 PM

Several dividend-paying stocks, including LIC and Hero MotoCorp, will trade ex-dividend next week, with record dates between July 23 and July 25, 2025. Investors must hold stocks before these dates to qualify for dividends.

Dividend stocks: LIC, Hero MotoCorp to Lupin ? these shares to trade ex-date soon

 22 Jul 2025 04:06 PM

Several dividend-paying stocks, including LIC and Hero MotoCorp, will trade ex-dividend next week, with record dates between July 23 and July 25, 2025. Investors must hold stocks before these dates to qualify for dividends.

Drug companies set for improved revenue growth in June quarter amid US market challenges

 22 Jul 2025 06:12 AM

Indian pharma and healthcare companies anticipate improved revenue and profit in the June 2025 quarter, fueled by domestic market growth. However, US pricing pressure, particularly for Revlimid generics, may impact some firms. Hospital chains are poised for better performance due to increased operational beds, while individual companies like Lupin expect strong US growth and margin expansion.

Lupin: Pithampur Unit-2 Gets Four FDA Observations; Company Promises Full Compliance And Quick Fixes

 17 Jul 2025 09:55 PM

Lupin: Pithampur Unit-2 Gets Four FDA Observations; Company Promises Full Compliance And Quick Fixes

Lupin: Company Gets GMP Certification From TGA Australia For Dabhasa API Facility 🏭🇦🇺

 17 Jul 2025 06:05 PM

Lupin: Company Gets GMP Certification From TGA Australia For Dabhasa API Facility 🏭🇦🇺

Avoid pure play brokerage firms, go for wealth management stocks: Hemang Jani

 17 Jul 2025 12:50 PM

Hemang Jani suggests caution towards pure-play brokerage firms due to their F&O volume reliance, favoring wealth management companies like Nuvama and HDFC AMC. SBI's QIP is viewed positively, while Tech Mahindra's results were mixed, with communication segment showing promise. Glenmark's recent surge makes it less attractive currently, but Aurobindo Pharma and Lupin are favored in the pharma sector.

Lupin launches generic ophthalmic medication in US

 16 Jul 2025 04:25 PM

Lupin, an Indian drug firm, has introduced a generic eye medication in the US. This medication, Loteprednol Etabonate Ophthalmic Suspension, treats eye inflammation and pain. It is a bioequivalent to Bausch & Lomb's Lotemax. The drug addresses post-surgery inflammation and allergic conjunctivitis. The US market for this medication has annual sales of USD 55 million.

Lupin: Company Introduces Loteprednol Etabonate Ophthalmic Suspension, 0.5% In The U.S. 🇺🇸👁️

 16 Jul 2025 03:28 PM

Lupin: Company Introduces Loteprednol Etabonate Ophthalmic Suspension, 0.5% In The U.S. 🇺🇸👁️

Lupin signs $50 million licensing deal with Zentiva to commercialise Certolizumab Pegol across global markets

 09 Jul 2025 03:32 PM

Lupin Ltd has partnered with Zentiva Group to commercialize its biosimilar 'Certolizumab Pegol' across global markets. The agreement grants Zentiva commercialisation rights outside the US and Canada, primarily in Europe and CIS markets. Lupin will receive up to USD 50 million in milestone payments.

Lupin: Company Set to Receive $10 Million Upfront Payment and Potential Total of $50 Million for Development and Regulatory Milestones. 💰📈

 09 Jul 2025 02:27 PM

Lupin: Company Set to Receive $10 Million Upfront Payment and Potential Total of $50 Million for Development and Regulatory Milestones. 💰📈